Loading...
•
Mar 30, 2024
Masimo Q1 2024 Earnings Report
Reported first quarter 2024 financial results.
Key Takeaways
Masimo's consolidated revenue was $492.8 million, with healthcare revenue at $339.6 million and non-healthcare revenue at $153.2 million. The company reported a GAAP net income per diluted share of $0.35 and a non-GAAP net income per diluted share of $0.77.
Consolidated revenue reached $492.8 million.
Healthcare revenue amounted to $339.6 million.
Non-healthcare revenue totaled $153.2 million.
GAAP net income per diluted share was $0.35, while non-GAAP net income per diluted share was $0.77.
Masimo
Masimo
Forward Guidance
Masimo provided estimates for its second quarter 2024 and updated full-year 2024 guidance.
Positive Outlook
- Consolidated revenue is expected to be between $480 million and $510 million for Q2 2024 and between $2,055 million and $2,165 million for the full year 2024.
- Healthcare revenue is projected to be between $330 million and $340 million for Q2 2024 and between $1,355 million and $1,385 million for the full year 2024.
- Non-healthcare revenue is anticipated to be between $150 million and $170 million for Q2 2024 and between $700 million and $780 million for the full year 2024.
- Consolidated operating income is estimated to be between $33 million and $38 million (GAAP) or $67 million and $72 million (Non-GAAP) for Q2 2024.
- Consolidated earnings per diluted share are expected to be between $0.26 and $0.33 (GAAP) or $0.73 and $0.79 (Non-GAAP) for Q2 2024.
Challenges Ahead
- The estimates are based on current expectations and are subject to uncertainties and factors that could cause actual results to differ materially.
- Risks include dependence on Masimo SET® and Masimo rainbow SET™ products, competition, and failure to develop innovative products.
- The guidance is subject to the company's ability to manage cost structure and the pace of recovery in inpatient volumes.
- Potential uncertainty during the pendency of any such potential separation that could affect Masimo’s financial performance
- Negative effects of the announcement or pendency of any such potential separation on the market price of Masimo’s securities and/or on the financial performance of Masimo